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ABSTRACT - Esthesioneuroblatoma (ENB) is a rare tumor arising from the olfactory epithelium of the nasal
vault which frequently invades the cranial base, cranial vault and orbit. ENB has a bimodal age distribution
between 11 and 20 years and between 51 and 60 years. ENB accounts for approximately 1 to 5% of intranasal
cancers and no consensus has been reached regarding treatment of this tumor. We report on a 66 year old
female patient with a Kadish stage C tumor with frontal lobe invasion  submitted a total craniofacial resection
with a combined head neck and neurosurgeon team. The purpose of this study is to analyze the natural
history, treatment and prognosis of this tumor, based on the literature review.
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Estesioneuroblastoma: relato de caso
RESUMO - Estesioneuroblastoma é um tumor raro originado do epitélio olfactivo, frequentemente invadindo
a base do crânio e a região orbitaria. É tumor que pode ser encontrado em qualquer idade mas apresentando
dois picos de frequência entre 11 e 21 anos e 51 e 60 anos, raros em criança. A distribuição por sexo é
praticamente igual mas com uma pequena predominância masculina. O diagnostico histopatológico é feito
de forma definitiva por métodos imunohistoquímicos. A sintomatologia clínica corresponde ao de uma neoplasia
intranasal ou frontobasal. Devido a raridade destes tumores não se chegou ainda a um consenso em relação
ao tipo de tratamento. Relatamos o caso de uma paciente 66 anos de idade com um tumor classificado como
Kadish tipo C, com invasão dos seios da face e lobo frontal, que foi submetida a ressecção crânio facial por
uma equipe multidisciplinar. A historia natural o tratamento e o prognóstico dos pacientes portadores destes
tumores serão analisados baseando-se numa revisão da literatura.
PALAVRAS-CHAVE: estesioneuroblastoma, cirurgia crânio facial, cirurgia da base do crânio.
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Esthesioneuroblastoma (olfactory neuroblasto-
ma) (ENB) is a rare neuroepithelial tumor that arises
from the olfactory epithelium in the cribriform place
or nasal cavity1. First described in 1924 by Berger2 it
has a histological pattern similar to that of sympathe-
tic ganglia, retina, and adrenal medulla2 and only
recently3 became recognized as a distinct pathologic
entity probably as a result of immunohistochemis-
try and by means of electron microscopy techniques.
They have helped differentiate ENB from similar un-
differentiated nasal cavity tumors3. ENB account for
1 to 5% of malignant neoplasm of the nasal cavity.
Fewer than 945 cases are reported in the world lit-
erature4, and most of the reports were in small series.
Unlike most other neuroectodermal tumors, which
manifest in childhood, ENB, has a bimodal age dis-
tribution between 11-20 years and 51-60 years5. The
symptoms are related to sites and invasion of the
tumor. The staging system based on tumor exten-
sion that was presented by Kadish et al.6 in 1976
has been widely accepted. The treatment of choice
is a multidisciplinary craniofacial surgical resection
that has improved considerably the prognosis.
The purpose of this study is to analyze the natu-
ral history, treatment and prognosis of this tumor,
based on the literature review.
CASE
A 66 years old woman with a one year history of con-
stant bifrontal facial headache, nasal obstruction, anosmia
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has presenting for about two months visual blurring,
lacrimatiom and ocular pain followed one week later by
epistaxis. Physical examination revealed a bilateral nasal
mass that was endonasal endoscopy biopsy-proven to be
an ENB. CT and MRI (Fig 1) demonstrated that the tumor
filled the entire nasal cavity, ethmoid sinuses, sphenoid
sinus, and left frontal sinus. The tumor invaded the cribri-
form plate and the left frontal lobe. The patient under-
went a craniofacial resection with a combined neurosur-
geon and head neck surgeon team. A bicoronal incision
with frontal craniotomy, and in bloc resection of the frontal
tumor and frontal base with preservation the pericranial
flap, that was placed along the floor of the anterior cra-
nial fossa and sutured to the residual sphenoid bone as
well as though the residual dura, combined with an ex-
tended lateral rhinotomy, with totally resection of the in-
fra cranial tumor. In the post operatively MRI (Fig 2), no
tumor was found. The patient receives 56 Gy of external
beam radiotherapy over a 6-week period, and chemo-
therapy. She showed no recurrence after one year.
Fig 1. Preoperative sagittal MRI of the tumor, involving the ethmoid sinus, sphenoid sinus, nasal
cavity and frontal lobe.
Fig 2. Postoperative one month sagittal MRI, with no more tumor.
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DISCUSSION
Esthesioneuroblastoma is a very rare malignancy
of the neuroepithelium. It was first described by
Berger et al. in 1924, as “l´esthesioneuroepitheliome
olfactif”2 and was only introduced into the American
literature by Schall and Lineback7 in 1951. Nearly all
of the 945 cases have been reported within the last
40 years. Embryologically, the olfactory nerves de-
velop from the olfactory placode present in the fetal
olfactory mucosa8,9. Histologically, there are a num-
ber of criterias that help in its diagnosis: neuroepi-
thelial cells arranged in the classic pseudorosette
pattern; fibrillar intracellular background; marked
microvascularity; and round or fusiform cells appro-
aching the size of lymphocytes with poorly defined,
almost nonexistent cytoplasm1,10,11. Correct diagno-
sis often requires confirmatory examination with
electron microscopy for the detection of neurosecre-
tory granules. More recently immunohistochemical
methods for detection of neuronspecific enolase
(NSE) and S-100 protein with negative epithelial,
muscle, and lymphoid antigens allowed further con-
firmation of ENB1,12. This tumor must be differenti-
ated from neoplasm of the nasal cavity and paranasal
sinus, such as lymphoma, sarcoma, plasmacytoma,
malignant melanoma, anaplastic carcinoma, rhab-
domyosarcoma, and transitional cell carcinoma11,13.
ENB has a bimodal age distribution with an early
peak from 11 to 20 years and a later peak between
51 and 60 years of age10. Our patient was a 66 years
old woman. There is a slight male predominance13.
The staging system based on tumor extension that
was presented by Kadish et al.6 in 1976 has been
widely accepted. This staging system is predictive of
disease-related mortality. The system classifies pa-
tients with tumors limited to the nasal cavity as stage
A. Patients with tumors involving the nasal cavity
and extending into the paranasal sinuses are stage
B, and stage C are tumors spreading beyond the nasal
cavity and paranasal sinuses, as our patient. This sys-
tem has been advocated by some, because of its sim-
plicity and acceptable prognostic efficacy. Recently,
Morita et al.14 justified a modified classification with
stage D tumors, presenting metastases in cervical
lymph nodes distant. Two other staging methods,
the Biller method15 and the Dulguerov method16,
have also been described and used.
ENB is a slow growing tumor and the patients
may have a history of progressive symptomatology
for months to years, our patient has a one-year evo-
lution. The presenting symptoms are nonspecific and
related to the sites and invasion of the tumor. The
most common finding on physical examination was
the presence of a nasal mass as our patient. Recur-
rent epistaxis is sometimes present. Penetration into
the cribriform plate can cause anosmia. Ophthalmo-
logical symptoms as ptosis, diplopia, visual blurring,
ocular pain, proptosis, and excessive lacrimatiom may
be found. Ear pain and otitis can result from tumor
obstructing the Eustachian tube. Frontal headache
suggests involvement of the frontal sinus. Cranial
nerves may also be affected inducing nerve paraly-
sis14,17. Alteration of mental status may be present if
frontal lobe is invaded.
The diagnosis and evaluation of staging of ENB
can be done by CT, which provides the best infor-
mation about the tumor invasion into bony struc-
tures12. The tumor is presented as a homogeneous
density mass, equal to or greater than the surround-
ing soft tissues. There are no tumor cysts or calcifi-
cations. Contrast enhancement was usually moder-
ate and homogeneous. Coronal images were of value
in evaluating extension to the orbital and through
the cribriform plate and the anterior cranial fossa12.
MRI shows a tumor hypointense to gray matter on
T1-weighted images and iso or hyperintense on T2-
weighted images. Gadolinium enhancement was
observed to some degree in all cases. Fat saturated
T1-weighted spin-echo images with and without
gadolinium enhancement of particular value in dif-
ferentiating enhancing tumor from post-obstructive
mucous debris and evaluating tumor extension to
the non-enhancing orbital fat12. MRI is more accu-
rate in depicting the exact margins of intracranial
tumor extension because of its multiplanar display
and superior tissue contrast12.
Metastasis occurs in about 10 to 30% of pati-
ents18,19. The most common sites for metastasis spre-
ad are the cervical lymph nodes, less frequent are
lung and pleura, brain, bone, spinal column, breast,
and abdominal viscera20,21. Metastasis to the central
nervous system is infrequent and usually identified
only at post-mortem examination5. In the spinal cord
80% of metastasis are in the cauda equine18.
Our patient underwent a combined craniofacial
approach utilizing a bicoronal flap for superior ex-
posure and a lateral rhinotomy for infracranial expo-
sure. Reconstruction varied according to the extend
of the surgical resection and resultant defect. We
do not use bony reconstruction of the floor of the
anterior cranial fossa and supraorbital areas, but the
pericranial flap is placed along the floor of the ante-
rior cranial fossa and sutured to the residual sphe-
noid bone and residual dura matter to obtaining a
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watertight dural seal. Fibrin glue is use to assist du-
ral seal and to secure a watertight closure. There are
great variations in treatment for ENB. Some series
advocate a protocol with surgery15,19-22, radiothera-
py6,10,19,23 alone, combined surgery and pre opera-
tive radiotherapy13,24, and combined surgery and pos-
toperative radiotherapy22,25. The optimum manage-
ment for ENB is probably surgery using the concept
first described in 1971 by Doyle and Payton26: radi-
cal surgery with a combined craniofacial approach12
taken by craniofacial team, including neurosurgery
and head neck surgery. This technique has provided
enhanced exposure and the possibility to achieve
gross total resection. In patients without extension
of tumors to the superior nasal vault or the cribriform
plate, an intracranial exploration and remove of the
floor of the anterior cranial fossa must be performed.
This approach has had a decrease incidence of local
recurrence1. It is proved that the bone in this area
may harbor tumor cells with a potential cause of
recurrence. This was done with our patient that had
an involvement of cribriform plate and frontal lobe.
We also used an adjuvant postoperative radiotherapy
with 50-60 Gy resulted in effective local control as
indicated by other authors10,27. Furthermore the ra-
diotherapy is recommend for palliative treatment27.
The role of systemic chemotherapy in the treatment
of ENB has range from no response28-32, palliation20,33,
partial14,33-37 and complete response36,38,39. In general
chemotherapy is usually reserved for tumor spread-
ing beyond the nasal cavity and paranasal sinuses12,
or in the treatment of distant metastases40.
Treatment complications with ENB are high. Vi-
sual impairment is the most common adverse ef-
fect13, because the location of the tumor is difficult
to deliver an adequate dose of radiation without ex-
ceeding the tolerance of critical structures such as
the brain, optic chiasm and orbits.
The prognostic factors in the management of ENB
are very controversy because of the small number of
patients presented in each series. Morita1 and Foote41
advocated that the only reliable survival predictor is
the tumor’s pathological grade (Hyams’ grading sys-
tem42). Polin31 was unable to find significant differen-
ce between survival of patients with low and high-
grade tumors. Some authors16,43 affirm that the nega-
tive prognostic include age, metastasis, recurrence,
and extensions to the etmoidal, nasopharyngeal and
orbital area. They also noted that the absence of me-
tastasis does not necessarily confer a good progno-
sis. Goldsweig34 concluded that the degree of resec-
tability of the tumor on primary surgery is the best
predictor of long-term survival. Irish determined a
100% 2-year survival rates in patients undergoing
combined surgical and radiation treatment. Polin31
informs the 5 and 10 years survival rates of 87 and
54% respectively and a 97% one year survival. Pa-
tients with stage C disease have 96% one-year sur-
vival, 71% five years and 44% 10 years survival31. In
the series of Jekunen40 the median survival time for
11 patients was 27 months, and the median disease-
free was 27 months. In the literature the 5-year re-
currence free survival is report to be between 52%
and 90%16,29,40.
ENB recurs locally in up to 60% of patients who
undergo surgery15, and its locally aggressive behav-
ior is the most common cause of death44. Median
survival after recurrences was only 12 months45,46.
The majority of recurrences occur within the first few
years after treatment.
In conclusion, ENB is a very uncommon malig-
nant tumor arising from olfactory epithelium, that
have a long natural history characterized by frequent
local or regional recurrence. Radical craniofacial re-
sections by a multidisciplinary surgical team com-
bined with adjuvant radiotherapy with 50-60 Gy, is
probably the most usual treatment. The role of sys-
temic chemotherapy in the treatment of distant
metastasis should be further evaluated.
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